01—Abstract
Summary
Summary of the 10-Q filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. reported a strong first quarter for fiscal year 2025, demonstrating robust revenue growth driven by its U.S. Healthcare Solutions segment.
Total revenue for the quarter increased by 10.3% year-over-year, reaching $75.5 billiona, with the U.S. segment experiencing a significant 11.4% rise. This growth was bolstered by strong unit volume increases, notably a 36.1% surge in sales of GLP-1 class drugs for diabetes and weight loss, totaling $2.2 billion. Net income attributable to Cencora, Inc. rose to $717.9 million, a substantial increase from $420.8 million in the prior year's first quarter, translating to diluted earnings per share of $3.68.
The company also benefited from a substantial gain related to antitrust litigation settlements, contributing significantly to the increase in gross profit. Despite increased operating expenses, largely due to the recent acquisition of Retina Consultants of America (RCA) and associated integration costs, the company managed to expand its operating income by 87.3% year-over-year to $1,036.2 millionb. Cencora also highlighted continued capital allocation through share repurchases and dividend payments.
02—Key points
Key Highlights
- Revenue increased by 10.3% to $75.5 billion in Q1 FY25, driven by the U.S. Healthcare Solutions segment which saw an 11.4% rise.
- Sales of GLP-1 class drugs for diabetes and weight loss grew by 36.1% ($2.2 billion) year-over-year, a key driver of revenue.
- Net income attributable to Cencora, Inc. significantly increased to $717.9 million from $420.8 million in Q1 FY24.
- Diluted earnings per share improved to $3.68, up from $2.09 in the prior year's comparable quarter.
- Gross profit saw a substantial increase of 20.6% to $3.1 billion, boosted by higher sales and significant gains from antitrust litigation settlements.
- Operating income grew by a strong 87.3% to $1.04 billion, reflecting improved operational efficiency and revenue growth, despite higher operating expenses.
- The company completed the acquisition of Retina Consultants of America (RCA) in January 2025, contributing to increased goodwill and integration expenses.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Cencora, Inc. kept $0.01.
- Revenue$75.45B100.0%
- Cost of revenue−$72.39B95.9%
- Gross profit$3.06B4.1%
- Operating costs−$2.02B2.7%
- Operating income$1.04B1.4%
- Interest, other & tax−$318.3M0.4%
- Net income$717.9M1.0%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed May 7, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $75.45B$68.41B | +10.3% |
| Cost of Revenue | $72.39B$65.88B | +9.9% |
| Gross Profit | $3.06B$2.54B | +20.6% |
| SG&A Expenses | $1.60B$1.39B | +15.2% |
| Operating Expenses | $1.72B— | — |
| Operating Income | $1.04B$553.26M | +87.3% |
| Net Income | $717.87M$420.77M | +70.6% |
| EPS (Basic) | $3.70$2.11 | +75.4% |
| EPS (Diluted) | $3.68$2.09 | +76.1% |
| Shares Outstanding (Basic) | 193.80M199.41M | −2.8% |
| Shares Outstanding (Diluted) | 195.09M201.18M | −3.0% |
05—Questions
Frequently Asked Questions
What drove the significant increase in revenue for Cencora in the first quarter of fiscal year 2025?
Revenue increased by 10.3% year-over-year to $75.5 billion, primarily due to strong performance in the U.S. Healthcare Solutions segment. This growth was driven by increased unit volumes, particularly a significant rise in sales of GLP-1 class drugs for diabetes and weight loss, which grew by 36.1% ($2.2 billion). Increased sales of specialty products to physician practices and health systems also contributed to the growth.
How did the acquisition of Retina Consultants of America (RCA) impact the financial results?
The acquisition of RCA, completed in January 2025, contributed to increased revenue and goodwill on the balance sheet. It also led to higher operating expenses, specifically acquisition-related deal and integration expenses, and contributed to the growth in the U.S. Healthcare Solutions segment's operating income. The financial statements reflect RCA's results of operations since the acquisition date.
What is the current status of Cencora's litigation liabilities, particularly related to opioids?
Cencora's accrued litigation liability related to opioid settlements was $4.7 billion as of March 31, 2025. This liability is expected to be paid over the next 14 years, with approximately $416.5 million estimated to be paid before March 31, 2026. The company continues to defend itself in ongoing litigation and investigations.
How has Cencora managed its debt and liquidity?
Cencora has a diversified debt structure, including fixed-rate and variable-rate debt. In the first quarter of fiscal year 2025, the company issued new senior notes and a term loan, totaling $1.8 billion and $1.5 billion respectively, to finance the RCA acquisition. The company has significant availability under its credit facilities and generated $632.5 million in cash flow from operations during the six months ended March 31, 2025, indicating strong liquidity to manage its obligations, including debt repayment and dividends.
06—Continue